Interestingly, they found that almost 50% of metastatic CRC patients with wild-type KRAS and eligible for EGFR therapy had aberrations observed in RAS through cfDNA sequencing, thus not benefiting from anti-EGFR therapies [97]. The gene discussed is EGFR; the disease is colorectal carcinoma.